Abstract IFN, produced during viral infections by accessory (type I IFN) or NK cells (type II IFN), play a primary role in the regulation of immune and anti-viral NK cell effector functions. Because IFN have anti-proliferative effects on several cell types, including hematopoietic cells, we asked whether they modulate proliferation of human NK cells, and whether IFN-a and IFN-g mediate distinct effects on NK cells at different developmental stages. Analysis of proliferation at the single-cell level in human NK cells indicated that both IFN types inhibit IL-4-induced accumulation of immature CD56 ± IL-13 + NK cells in freshly separated peripheral blood lymphocytes and in cells derived from them after short-term cultures. However, IFN-g inhibited speci®cally the IL-4-dependent proliferation of these cells without affecting the IL-2-dependent one or that of the IL-13 ± cells, whereas IFN-a attenuated proliferation of NK cells at any developmental stage (both immature CD56 ± IL-13 + and mature CD56 + IL-13 ± IFN-g + NK cells) and contributed to their monokine-induced differentiation to IFN-g-producing cells. Adding to our previous report that IL-13 inhibits accumulation of mature IFN-g + NK cells, the present data unravel a mechanism by which peripheral immature IL-13 + and mature IFN-g + NK cells can negatively regulate each other's accumulation.
Introduction
Accessory cells ®rst interacting with pathogens produce cytokines that activate NK cell cytotoxic effector functions and stimulate them to initiate in¯ammatory immune responses via IFN-g production. Among these, IL-12, produced after the initial wave of IFN-a and tumor necrosis factor (TNF)-a by monocyte/macrophages and dendritic cells (DC) [reviewed in (1, 2) ], plays a primary role as the most potent inducer of IFN-g production (3) . IFN-a, primarily produced by plasmacytoid DC upon viral infection (4), enhances cytotoxicity and initiates ef®cient in¯ammatory type 1 responses by increasing expression of the signal transducing subunit of the IL-12 receptor (IL12Rb2) (5) , also regulated by IL-18 (6) , and inducing production of IL-15 (7), a cytokine allowing proliferation/survival of both T and NK cells.
Peripheral NK cells in humans include a major CD56 + population and a minority of CD56 ± cells that produce IL-13, about one-third of which are also IL-5 + (8) . IL-13 + NK cells are immature and do not produce IFN-g (8, 9) . In the presence of IL-12, they develop to lose ability to produce type 2 cytokines, while gaining that to produce IFN-g and phenotypic/functional characteristics of mature NK cells (9, 10) . Like relatively immature hematopoietic cells of other lineages, and unlike mature IFN-g + NK cells, the IL-13 + NK cells have high proliferative potential. Preferential proliferation of a proportion of these IL-13 + cells accounts for the accumulation of type 2 cytokine + NK cells in response to 9) , a cytokine capable of inhibiting the effects of IL-12 on IFN-g production and regulation of NK cell terminal differentiation (8) . In the presence of IL-2, instead, part of the CD56 ± IL-13 + cells partially mature to become CD56 + , remaining IL-13 + IFN-g ± . The population still CD56 ± in these cultures may contain cells that, phenotypically identical to most peripheral IL-13 + NK cells, are possibly less functionally mature.
Human NK and T cell terminal development, including that of the a-galactosyl ceramide-reactive NKT population (11) , is strikingly similar and the sequence reported to occur in vitro for human cells has been con®rmed to occur in vivo during NKT cell thymic development (12) . Terminal T cell development is recapitulated in vitro using a combination of four accessory cell-produced monokines (IL-12, IL-18, IFN-a and IL-15). Each of these affects NK cell functions, e.g. IFN-a enhances cytotoxicity; IL-18 and IL-2 combined enhance IFN-g production (6) ; and, in the mouse, type I IFN are reportedly involved in inducing NK cell proliferation in vivo (13) .
IFN-g, unlike IFN-a, has no consistent effect on NK cell functions (14) , but like IFN-a it mediates anti-proliferative effects on numerous cell types, including immature hematopoietic cells of several lineages (15, 16 ). An inhibitory effect of IFN-g on immature NK cell proliferation, and possibly facilitated differentiation to mature effector IFN-g + NK cells, may, in part, explain the observation that NK cells from IFN-g ±/± mice produce levels of IL-13 higher than those produced by the IFN-g-suf®cient parental strains (17) . Here, we asked whether IFN modulate accumulation of human peripheral blood NK cells at different developmental stages by exerting antiproliferative effects and/or contributing to their differentiation to IFN-g + cells, testing the hypothesis that, like in T cells, IFN-a in combination with the monokines IL-12, IL-18 and IL-15 facilitates terminal NK cell differentiation.
Methods

Cell populations and culture conditions
Peripheral blood lymphocytes (PBL) were obtained from healthy adult and neonatal (umbilical cord) blood as described (18) . Homogeneous polyclonal CD3 ± CD161 + CD56 ± immature NK cells populations were obtained from PBL by negative selection after a two-step puri®cation protocol involving sequential depletion of: (i) most mature T, B, NK cells and monocytes using a mixture of mAb to leukocyte differentiation antigens (CD3, CD4, CD5, HLA-DR, CD56 and NKp46) and indirect anti-Ig rosetting (18) , and (ii) possible residual mature NK cells by indirect immuno¯uorescence with anti-CD16 mAb and cell sorting with an Epics Elite¯ow cytometer (Beckman Coulter, Miami, FL) as previously described (9) . These cells were used after a 2-week culture with IL-2, IL-12-neutralizing mAb, phytohemagglutinin (Sigma, St Louis, MO)-L, and 50-Gy irradiated Daudi B lymphoblastoid, autologous and allogeneic mononuclear cells [culture conditions detailed in (9) ]. PBL and the CD56 ± immature NK cell populations were maintained in culture for 5±8 days in RPMI 1640 (Biowhittaker, Walkersville, MD) supplemented with L-glutamine, 5% autologous plasma, recombinant human cytokines and anti-cytokine mAb, as indicated. Puri®ed human rIFN-a, 500 U/ml [IFN-A/D (BglII)], was from PBL Biomedical (New Brunswick, NJ); rIFN-g from Escherichia coli, 500 U/ml, was provided by Dr H. M. Shepard (Genentech, South San Francisco, CA); and the neutralizing anti-IFN-g mAb used were B133.1 and B133.5 (19) . All other cytokines and mAb used were as previously reported (20) .
Induction of cytokine production and intracellular cytokine detection
Cytokine production was induced in fresh and cultured lymphocytes upon a 5-h stimulation with Ca 2+ ionophore A23187 (0.2 mg/ml), phorbol myristate acetate (PMA, 2 nM) (both from Sigma) and rIL-2 (100 U/ml) [Brefeldin A (Sigma) added, 10 mg/ml, during the last 3 h]. Stimulation, and combined detection of surface phenotype and intracellular IL-13, IL-5 and IFN-g accumulation were according to our previously reported protocols of multiple-color immuno¯uor-escence (9) . The total NK cell population was identi®ed based on the combined expression of CD56 and CD161 [B159. 5 
Carboxy¯uorescein diacetate succinimidyl ester (CFSE) analysis
To determine the numbers of divisions that cytokine + NK cells have undergone during culture, lymphocytes were cultured after labeling with CFSE (22) (0.25±0.75 mM, 10 7 cells/ml, 8 min, 37°C; Molecular Probes, Eugene, OR) as described (9) . After culture, CFSE content, intracellular IL-13 accumulation and surface phenotype were simultaneously analyzed by immuno¯uorescence (¯ow cytometry) in gated CD3 ± (CD56/ CD161) + cells according to previously published protocols (9). As previously described (9, 23) , based on viable cell counts and CFSE analysis, the minimum number of cells in the original population from which the IL-13 + NK cells detected at the end of the culture derived (minimum progenitor cell number) was calculated as (CFSE n + cell number/2 n ) + (CFSE n + 1 + cell number/2 n + 1 ) + ..., where n = division number, based on the discrete CFSE peaks. Details of the required (not shown) controls performed are given in (9) . The calculation itself assumes no loss of the cells of interest, due to cell death or differentiation-induced changes in the original cell phenotype and/or function during culture (e.g. loss of IL-13 production). However, cell loss (of precursor cells and/or their potential progeny) can be determined and this is essential for correct interpretation of CFSE analysis when the calculated minimum progenitor cell number is lower than that of the corresponding cells in the original population. Number of cells lost is calculated as: n = (cell number in the original population ± progenitor cell number) Q (average number of divisions the remaining cells have undergone).
Results
IFN-mediated inhibition of IL-4-induced accumulation of type 2 cytokine + NK cells
As previously reported, most peripheral NK cells produced low levels of IFN-g, but distinct proportions of NK cells, corresponding to functionally immature CD56 ± and mature CD56 + cells (9) , were detected producing respectively high levels of IL-13 (IL-13 + ) or IFN-g (IFN-g +/hi ) upon stimulation of freshly separated PBL [ (8) Given the inter-individual variability of the IL-13 + cell proportions and numbers among freshly isolated lymphocytes and cells cultured with IL-2 + IL-4 ( Fig. 1B, top) , the data were analyzed after normalizing proportions (and numbers) of IL-13 + NK cells after culture in the experimental conditions to those in the respective control (IL-2 only) cultures, as described in Methods and previously detailed (8, 9) (Fig. 1B , Fig. 2) . This was independent of IFN-a-induced endogenous IFN-g production, as IFN-g neutralization did not abrogate the inhibition. Addition of IFN-a to cultures with IL-2 only did not result in decreased proportions of IL-13 + NK cells, although their numbers were decreased by a factor similar to that for the total NK cells.
IFN-induced inhibition of NK cell proliferation
Both IL-2 and IL-4 induce NK cell proliferation, but IL-4 induces preferential proliferation of the IL-13 + NK cells within the total population (9) . Similar percentages of cells in the total and the IL-13 + NK cells from cultures of freshly isolated lymphocytes with IL-2 only (Fig. 3) had undergone the same numbers of divisions, as determined by CFSE analysis at the single-cell level. As expected, in cultures with IL-4, the proportions of IL-13 + NK cells that had undergone the highest numbers of divisions were substantially increased, whereas those in the total NK cell population were decreased. In cultures with IL-12, which prevents IL-13 + NK cell accumulation (8) by inducing their differentiation (9), the percentages of both total and IL-13 + NK cells that had undergone multiple divisions were similarly decreased. The lack of IL-13 + NK cell accumulation in cultures with IL-12 (not shown) was mostly independent of induced IFN-g production, since IFN-g neutralization minimally affected it.
To determine whether inhibition of proliferation accounts for the IFN-associated decrease in IL-13 + NK cell accumulation, the numbers of divisions undergone by NK cells were compared between lymphocytes from cultures with IL-2 + IL-4 without (control) and with added IFN-a or IFN-g (Fig. 4) . Neutralization of endogenously produced IFN-g resulted in modestly and minimally increased numbers of divisions by the IL-13 + and total NK cells respectively. The numbers of divisions undergone by the IL-13 + cells, or those undergone by both these and the total NK cells, were decreased after culture with added IFN-g and IFN-a respectively.
After culture with IL-4 and added IFN-g-neutralizing mAb or IFN-g, the numbers of total NK cells was about one-third those in the original population. In both cultures, this corresponded to a loss of~75% of the cells from which the viable cells in culture could have derived, calculated as indicated in Methods. Such loss is possible from pre-existing NK cells and/or from NK cells newly accumulated following proliferation. Similar calculations indicated that, although the IL-13 + NK cell numbers had increased 5.7-and 3.6-fold in the cultures with added IFN-g-neutralizing mAb or IFN-g, 60 and 40% of these cells had been lost respectively in the two culture conditions. The greater loss (75%) of total NK cells versus IL-13 + NK cells in the presence of IFN-g (40%) suggests that IFN-g inhibits proliferation of the IL-13 + cells rather than induces their differentiation and/or death. Instead, after culture with IFN-a, 85% of both total and IL-13 + NK cells had been lost. Given the 50% decrease of IL-13 + NK cells from their original numbers, this corresponded to a loss of IL-13 + cells 40% greater than that of the corresponding population in culture without IFN-a, suggesting that IFN-a, in addition to inhibiting IL-13 + NK cell proliferation, prevents survival of both these and total NK cells to a similar extent or induces loss of ability to produce IL-13. Thus, the two IFN types prevent accumulation of the IL-13 + NK cells in response to IL-4 via distinct mechanisms, with only IFN-g speci®cally inhibiting proliferation of the immature IL-13 + cells.
IFN-induced inhibition of functionally immature type 2 cytokine + NK cells
IL-13 + NK cells include an immature CD56 ± IFN-g ± and aǹ intermediate' CD56 + population, not necessarily IFN-g + (9). To determine whether IFN affect proliferation of NK cells at speci®c developmental stages, experiments similar to the above were performed with cells derived from cultures of immature homogeneous CD161 + CD56 ± IL-13 + NK cell populations with IL-2 (Fig. 5) . After culture, the cells, still CD161 + , contained CD56 ± and CD56 + cells, both including IL-13 + cells (20 and~1% respectively; not shown). Upon further culture with IL-2 + IFN-g-neutralizing mAb and IL-4, the percentages of cells that had undergone several rounds of divisions were increased, compared to those in cultures with IL-2 only, in the IL-13 + and, to a lesser extent, in the IL-13 ± immature cell population still CD56 ± . Proliferation of the total and the IL-13 + cells was not inhibited by exogenously added IFN-g, whereas that of both populations was decreased in cultures with added IFN-a, resulting in lower proportions of cells that had under- Fig. 5 . IFN-mediated effects on immature NK cell proliferation. Immature NK cells (obtained from CD3 ± CD61 + CD56 ± neonatal lymphocytes, see Methods) were labeled with CFSE and cultured for 5 additional days with IL-2, and the cytokines and mAb indicated at the right. After culture, the cells were stimulated, and IL-13 production and CFSE content were analyzed within gated CD3 ± CD61 + CD56 ± or CD3 ± CD56 + lymphocytes as described in Fig. 3 . Data presentation is as in Fig. 3 
Effect of monokines on immature NK cell differentiation
Immature CD56 ± IL-13 + NK cells are induced to differentiate to CD56 + IFN-g + cells in culture with IL-12 and B lymphoblastoid cell lines (9) . Immature, CD2 ±/lo IL-13 + T cells are similarly induced to differentiate in cultures with IL-12 and TCRmediated stimuli, concomitant with induced CD56 expression (8, 20) . The monokines IL-12, IL-15 and IL-18 combined with IFN-a suf®ce to induce the same effect substituting for TCRmediated stimulation, and, as expected, T cell differentiation is accompanied by decreased proliferation (20) . T and NK cells undergo the same developmental sequence, and IFN-a attenuates proliferation of NK cells at any developmental stage. Consequently, we asked whether, like for TCR stimulation, IFN-a in combination with IL-12 and IL-18 could substitute for feeder B cells to induce differentiation of homogeneous CD56 ± immature NK cell populations (Fig. 6) . IL-15 was included in all cultures to maintain NK cell survival. The NK cell numbers, compared to those in the original cell populations, increased~3-fold in all cultures without IL-12, were~50±75% higher in those with IL-12 (including those with added IFN-a or IL-18) and decreased by~20% in those with all monokines combined (not shown). The numbers of IFN-g + cells in cultures with added IFN-a or IL-18 individually were similar to those in control cultures with IL-15 only, but increased after culture with IFN-a + IL-18, mostly depending on increased numbers of IL-13 + IFN-g + cells. The numbers of IFN-g + cells were higher in all cultures with IL-12 added, despite reduced total NK cell numbers. The remaining IL-13 + cells in these cultures were mostly IFN-g + , with a few still IFN-g ± . The increased numbers of IL-13 + cells in the cultures with IFNa, but no IL-12, did not correspond to proportions of IFN-g + cells signi®cantly greater than those in the original population. The presence of IFN-a, per se, did not result in speci®c loss of immature IL-13 + NK cells. With IL-12 added, the IL-13 + NK cell numbers decreased in all culture conditions, with the highest proportions of IL-13 + IFN-g + cells detected when IL-18 and IFN-a were combined. IL-18, which had no effect on the proportions, numbers and accumulation of IL-13 + NK cells in cultures of freshly separated lymphocytes with or without IL-2 or IL-2 + IL-4, also had no effect on the proliferation of immature and mature NK cells (not shown). As expected in the case of induced differentiation, a proportion of the cells expressed CD56 after culture with the monokine combination (not shown). Thus, the same set of monokines can induce both T and NK cell differentiation from IL-13 + to IFN-g + cells; IFN-a, inef®cient alone, cooperates with IL-12 and IL-18 to maximize this process, still maintaining the highest numbers of type 2 cytokine + IFN-g + NK cells.
Discussion
Our data indicate that both IFN-a and IFN-g can inhibit IL-2 + IL-4-induced accumulation of type 2 cytokine + NK cells, but, importantly, they diverge in the NK cell speci®city of their effect. IFN-a attenuates proliferation of all (IL-13 ± and IL-13 + ) The observation that neutralization of IFN-g produced in response to IL-2 or IL-15 restores proliferation of IL-13 + NK cells indicates that physiologically relevant levels of IFN-g are effective to inhibit peripheral type 2 cytokine + NK cell accumulation. Although IFN-g inhibited speci®cally proliferation of the IL-13 + NK cells, its effects were minimal on those IL-13 + cells still CD56 ± after culture of peripheral immature CD56 ± NK cells. These apparently contrasting results are reconciled considering that the latter cells are likely functionally less mature than most peripheral blood CD56 ± IL-13 + cells. This is supported by the observations that, unlike other NK cell populations, these cells constitutively produce detectable IL-13 levels (8) (possibly in response to unde®ned physiologic stimuli), and proliferate in response to IL-2 and/or IL-4 more than the IL-13 + CD56 + cells differentiated in the same cultures and the freshly separated CD56 ± ones. Alternatively, differences in the response of freshly isolated and cultured immature NK cells to IFN-g might depend on lack of IFN-gresponsive accessory cells in the latter population. An IFN-ginducible factor produced by accessory cells [e.g. the type I IFN-k (25)] may mediate the block in proliferation. However, IFN-g affects only the IL-13 + population, making this possibility unlikely, unless the IL-13 + cells are more sensitive than the IL-13 ± ones to low levels of the putative IFN-g-induced factor(s). Whichever the mechanism, the observation that IFN-g inhibits the IL-4-induced, but not the basal or IL-2-induced, proliferation of NK cells is consistent with its lack of effect on most CD56 + NK cells, in which both the IL-13 ± and the minor IL-13 + NK cell population have minimal proliferative response to IL-4.
The molecular bases for the differential effects of IFN-a and IFN-g on IL-13 ± NK cells are to be de®ned. IL-4 receptor engagement activates several signaling pathways, including JAK1,3/STAT6, IRS1 and 2, Grb, and Shc (26) . Differences in developmental stage-dependent expression of IL-4 receptorassociated signaling molecules may dictate the extent of proliferative response to IL-4 in immature IL-13 + and mature IL-13 ± NK cells. Whether IL-4 signaling in the mature CD56 + cells involves pathways distinct from those affected by IFN-g in the IL-13 + NK cells remains to be determined.
The differential ability of the two IFN types to inhibit NK cell proliferation is a likely basis for complementing functions of IFN-a and IFN-g in in¯ammatory responses. IFN-a is one of the ®rst in¯ammatory mediators released by accessory cells in response to pathogens and/or tissue damage (14) . In an in¯ammatory reaction involving IFN-a production (e.g. viral infection), IFN-a, by inhibiting proliferation of most peripheral immature/intermediate IL-13 + cells (CD56 ± and CD56 + ) and sensitizing them to the effects of IL-12 via induced expression of signi®cant levels of functional IL-12R (5), would function to prime them to proceed to terminal differentiation in response to other maturation stimuli (i.e. IL-12 and IL-18 for both NK and T cells), concomitantly enhancing the effector functions of the terminally differentiated cells [e.g. cytotoxic potential of NK cells; antigen presentation by accessory cells; IFN-a and IL-15 production by monocytes and IFN-g by NK and T cells; reviewed in (14) ]. IFN-g is produced and acts at a later phase. By speci®cally inhibiting the default accumulation of residual immature lymphocytes that, via type 2 cytokine production, contribute to maintain monocytes in a relatively immature state, it would function to increase the ef®cacy of cellmediated immune responses, concomitantly inducing maturation of accessory cells.
IL-13 plays a primary role in allergic asthma-associated pathology [(27) , reviewed in (28)] and IL-13 + (IL-5 + ) NK cells are present in the mononuclear cell population found in the bronchoalveolar lavage from allergic asthmatic individuals analyzed ex vivo immediately after in vivo challenge with the relevant allergen (29) . Also, NK cell-derived IL-5 is critical in the pathogenesis of experimental allergic asthma in murine models (30) (IL-13 not tested). In the`allergy' context, NK cellderived IL-13 may prevent progression of IFN-g-associated, type 1 immune responses, and thus contribute to allergic pathology by inhibiting accumulation and maintenance of the IFN-g + NK cells independently of its ability to inhibit IL-12 production by accessory cells (8) . As a result of inhibition of their differentiation to IFN-g + cells, the contribution of immature NK cell-derived cytokines to atopic reactions may involve, in addition to IL-13, TNF-a, granulocyte macrophage colony stimulating factor and IL-5 (all expressed at the highest levels in immature NK cells) (10) . These cytokines affect B cell survival (31) and Ig switching to non-in¯ammatory (IgG2) and FceR-triggering (IgE) isotypes/classes, the latter directly inducing mast cell degranulation, and promote mobilization and survival of myeloid cells (basophils, mast cells and eosinophils) pathogenic in allergic reactions (32) .
We previously reported that IL-13 prevents accumulation of IFN-g + , but not total, NK cells (8) . Here we show that IFN-g speci®cally prevents accumulation of the IL-13 + NK cells. Most peripheral NK cells produce either IL-13 or IFN-g exclusive of each other (8) . Thus, a negative feedback loop can be established between immature and mature NK cells, and maintenance of peripheral NK cells at either developmental stage does not depend on autocrine functions of the respective NK cells, but is controlled by cytokines produced exclusively by their progenitors or their differentiated progeny. This is unlike T cells which, at any developmental stage, can maintain their own survival via production of autocrine growth factors, i.e. IL-2 and IL-4. Because T and NK cells share the same developmental pathway (11, 20) , IFN may similarly inhibit type 2 T cell accumulation. However, differences in responses to IFN are possible between type 2 CD4 + and CD8 + cells, since IL-4 enhances proliferation only of the latter (23) , and between T and NK cells, depending on modulated expression and responsiveness of IFN receptors possibly induced in T cells upon TCR engagement.
